Hold CL at current sizing with explicit $87/$93.50 trigger framework and Q3 2026 print as forcing event
Hold is correct because the structural bull thesis (volume-led growth, margin expansion, Dividend King with $3.5B FCF and 0.33 beta, 87% Polymarket no-cut probability supporting yield competitiveness) is durable enough to preserve core ownership, but the asymmetry math (1.24:1 risk-reward), broken 50 SMA/MACD technicals, the fresh Q2 EPS -5.5% print, and two months of catalyst risk until Q3 reporting preclude the conviction required for Buy. The $87-$93.50 trigger framework and $89.58 stop convert the passive Hold into a defined-actionable stance rather than a directional long with a known alpha ceiling.
| Position | Action |
|---|---|
| at ~$91 current price | Do NOT add fresh capital; maintain current position size |
| $87.00 pullback to 200 SMA with confirmed hold | Add to position with stop below $85.50 |
| Confirmed close above $93.50 on volume >6M with MACD turning positive | Add to position on breakout confirmation |
| $89.50-$90.50 support zone with stop below $89.00 | Measured add if support holds and flexible double-confirmation met |
Colgate-Palmolive is the strongest setup in consumer staples right now, offering a high-quality compounder with raised guidance, accelerating volumes, and 2.32% yield in a macro environment that increasingly rewards defensive ballast over beta.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 91.63 | neutral |
| close_200_sma | 86.41 | bullish |
| close_10_ema | 91.50 | neutral |
| macd | -0.08 | bearish |
| macd_signal | 0.05 | neutral |
| rsi | 48.97 | neutral |
| boll_bands | mid 91.91 / ub 94.24 / lb 89.58 | neutral |
| vwma | 91.84 | neutral |
Support: 89.58 · 89.7 · 86.41 | Resistance: 93.49 · 94.24 · 97.97
CL exhibits a confirmed long-term uptrend (price 5.7% above 200 SMA at $86.41) but is in a multi-week consolidation phase within a $89.58–$94.24 range. Momentum is neutral with RSI at 48.97 and near-zero MACD (-0.08 vs signal 0.05). Volatility is contained (ATR $2.03). The 50-day SMA ($91.63) and Bollinger middle ($91.91) serve as pivot/mean levels. Recommendation: HOLD awaiting breakout trigger above $93.50 (bullish) or breakdown below $89.58 (bearish).
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $93.50 on volume >6M with MACD turning positive
Then: Add position
The 0.3% distance below the 50-SMA is noise, not signal, with the structural uptrend intact well above the 200-SMA.
↩ rebuts: “Bear's 'below 50-day SMA' technical concern”
· concedes: Bear's depressed trailing P/E (36x) is a real number from the past, though it reflects a non-recurring impairment; Bear's 'below 50-day SMA' technical observation is technically accurate at 0.3%, though it's noise rather than a regime shift
Colgate-Palmolive's "best setup in staples" is actually a trap: the stock trades at a demanding 22x forward P/E that prices in a 62% earnings recovery that hasn't materialized (Q2 EPS actually fell 5.5% YoY), sits below key technical levels after a six-week stall following a February peak, and faces structural risks including negative tangible book value, a razor-thin FCF buffer, and currency headwinds—all while offering a 2.32% dividend yield that underperforms risk-free Treasuries.
EV: -$5.40 to -$11 (from $91.33 to $86.40-$80) · concedes: The Q4 2025 impairment of $919M is real and correctly normalized to derive the $3.50-$3.60 adjusted EPS figure; Colgate is a quality franchise with strong brands; Dividend has a 63-year streak, demonstrating management commitment; The defensive rotation thesis has some merit if Iran/Hormuz disruption escalates; Hill's Pet Nutrition at 3-4% volume growth is the strongest part of the business
→ vs conservative: Focusing on 5.5% EPS decline while ignoring 19% operating income growth, 140 bps margin expansion, and three consecutive quarters of volume growth is shallow analysis; raised 2026 guidance after the 'miss' tells you how to read the headline
→ vs conservative: Characterizing 22.4x forward P/E as 'rich valuation' ignores peer parity with P&G (21x), Kimberly-Clark (22x), and Unilever (19x); Colgate has arguably the best margin expansion story in the category at this valuation
→ vs conservative: The 'rich valuation' narrative ignores that TTM P/E of 36x is an artifact of Q4 2025 impairment creating a depressed earnings base
→ vs conservative: Palm oil and packaging resin cost concerns are overblown — Q2 2026 delivered 140 bps margin expansion DESPITE these headwinds; bears have been wrong on margin compression for two years
→ vs conservative: The 87% probability of no Fed rate cuts in 2026 is a macro TAILWIND for Colgate: 2.32% dividend yield with increases becomes more attractive vs. cash; defensive names see capital rotation IN during geopolitical risk
→ vs neutral: The consolidation/range-bound technical action is not a problem but a GIFT — coiled setup at logical entry zone before Q3 2026 earnings validation
→ vs neutral: RSI at 49 (neutral, not overbought), MACD essentially flat at -0.08, and price well above 200 SMA indicate a stock coiling for breakout, not a stock in trouble
→ vs neutral: Historical precedent: CL traded below 50 SMA multiple times during January-February rally to $98 and never looked back; 'below 50 SMA' concern is meaningless noise
→ vs neutral: Waiting for 'confirmation' before adding means paying 5-7% more when Q3 earnings validate the thesis and the stock gaps higher
→ vs neutral: The HOLD symmetric decision assumes no edge — but there are multiple edges: volume-led growth, margin expansion trajectory, dividend durability, FCF coverage, declining leverage, and coiled technical setup
Market Capitalization
~$73.4B
Share Price (Implied)
~$92.07
52-Week High
$99.33
52-Week Low
$74.55
50-Day Moving Average
$91.87
200-Day Moving Average
$87.25
Beta
0.327
Dividend Yield
2.32%
P/E Ratio (TTM)
36.24x
Forward P/E
22.41x
PEG Ratio
1.75
EPS (TTM)
$2.54
Forward EPS
$4.11
Price/Book
311.01x
Q2 2026 Revenue
$5,361M
Q2 2026 Gross Profit
$3,296M
Q2 2026 Operating Income
$1,016M
Q2 2026 Net Income
$693M
Q2 2026 Diluted EPS
$0.86
Gross Margin (TTM)
60.4%
Operating Margin (TTM)
21.0%
Net Profit Margin (TTM)
9.7%
TTM EBITDA
$4,983M
FY2021 Revenue
$17,967M
FY2022 Revenue
$19,457M
FY2023 Revenue
$20,101M
FY2024 Revenue
$20,382M
FY2024 Net Income
$2,132M
FY2024 Diluted EPS
$2.63
TTM Diluted EPS
$2.54
FY2025 Net Income (TTM)
$2,038M
Total Assets (Q2 2026)
$16,790M
Stockholders' Equity (Q2 2026)
$236M
Total Debt (Q2 2026)
$7,857M
Net Debt (Q2 2026)
$6,487M
Cash (Q2 2026)
$1,370M
Goodwill & Intangibles (Q2 2026)
$4,595M
Working Capital (Q2 2026)
+$160M
Current Ratio (Q2 2026)
1.026
Operating Cash Flow (TTM)
$4,544M
CapEx (TTM)
($598M)
Free Cash Flow (TTM)
$3,458M
Dividends Paid (TTM)
($1,822M)
Share Repurchases (TTM)
($1,291M)
Net Debt Issuance (TTM)
($370M)
Q2 2026 Operating Cash Flow
$995M
Q2 2026 CapEx
($128M)
Q2 2026 Free Cash Flow
$867M
Q2 2026 Dividends Paid
$462M
Q2 2026 Share Repurchases
$291M
Q2 2026 Net Debt Change
($89M)
ROA
15.8%
Net Debt/EBITDA
1.3x
Interest Coverage
15.8x
Dividends + Buybacks (TTM)
$3.1B
Implied Upside to 52-Week High
~7.9%
Implied Downside to 52-Week Low
~-19%
Q4 2025 Impairment Charge
$919M
Strengths
Concerns
Colgate-Palmolive is a mega-cap consumer staples company with a $73.4B market cap trading near its 52-week high. The stock shows solid fundamentals including 60.4% gross margins, 21% operating margins, and $3.46B TTM free cash flow (4.7% FCF yield), while net debt has declined to $6.49B from $7.99B in 2021. However, the trailing P/E of 36.24x appears elevated due to Q4 2025's $919M impairment charge depressing TTM EPS to $2.54, though forward P/E of 22.41x reasonably prices in a rebound to $4.11 EPS; the 2.32% dividend yield with aristocrat status provides income support, and the 0.33 beta offers defensive portfolio characteristics, but limited near-term upside and high payout ratio (~89%) warrant a balanced HOLD stance for new investors awaiting a pullback toward the 200-day moving average (~$87).
Macro: The macro backdrop is mixed-to-headwind for consumer staples: PCE inflation is re-accelerating, the Fed is overwhelmingly expected to remain on hold through 2026 (87% no-cut probability), and oil/energy costs are elevated due to Iran/Hormuz disruption (~519 Mb global inventory draws Feb–Aug 2026). Soft-landing consensus remains intact with US recession odds at only 8%, which reduces urgency to rotate into defensives. Higher-for-longer rates support CL's dividend yield premium but also firm the dollar (headwind to international revenue). The Iran situation presents a dual-edge: oil-driven input cost inflation is negative for margins, but geopolitical escalation could trigger defensive rotation into XLP. AI/Nvidia risk-on narrative caps relative defensive beta near-term. Dollar-store earnings this week will be a key consumer-health signal for mass-channel volumes relevant to CL's value-tier SKUs.